Acelyrin, Inc. (NASDAQ:SLRN) Shares Bought by Deutsche Bank AG

Deutsche Bank AG lifted its stake in shares of Acelyrin, Inc. (NASDAQ:SLRN) by 53.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 70,000 shares of the company’s stock after buying an additional 24,356 shares during the period. Deutsche Bank AG owned approximately 0.07% of Acelyrin worth $220,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Bank of America Corp DE lifted its stake in shares of Acelyrin by 10.7% during the fourth quarter. Bank of America Corp DE now owns 197,835 shares of the company’s stock worth $621,000 after buying an additional 19,165 shares during the period. BNP Paribas Financial Markets purchased a new position in shares of Acelyrin during the fourth quarter worth $236,000. Algert Global LLC raised its holdings in shares of Acelyrin by 18.9% during the fourth quarter. Algert Global LLC now owns 77,060 shares of the company’s stock worth $242,000 after purchasing an additional 12,230 shares during the last quarter. Alyeska Investment Group L.P. purchased a new position in shares of Acelyrin during the fourth quarter worth $4,760,000. Finally, Almitas Capital LLC raised its holdings in shares of Acelyrin by 506.5% during the fourth quarter. Almitas Capital LLC now owns 148,704 shares of the company’s stock worth $467,000 after purchasing an additional 124,185 shares during the last quarter. 87.31% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Acelyrin news, CEO Mina Kim sold 17,986 shares of Acelyrin stock in a transaction on Monday, March 17th. The shares were sold at an average price of $2.74, for a total value of $49,281.64. Following the completion of the transaction, the chief executive officer now owns 671,753 shares of the company’s stock, valued at approximately $1,840,603.22. The trade was a 2.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 13.60% of the stock is currently owned by corporate insiders.

Acelyrin Price Performance

Shares of Acelyrin stock opened at $2.27 on Tuesday. The firm has a fifty day moving average price of $2.32 and a 200 day moving average price of $2.69. Acelyrin, Inc. has a 1 year low of $1.85 and a 1 year high of $7.25. The stock has a market cap of $229.17 million, a PE ratio of -0.92 and a beta of 1.07.

Acelyrin (NASDAQ:SLRN) last issued its earnings results on Wednesday, May 14th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.95) by $0.40. As a group, equities analysts expect that Acelyrin, Inc. will post -2.53 EPS for the current year.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.